bristol-myers squibb pfizer alliance logo

This information is intended for healthcare professionals based in Ireland.

Eliquis (Apixaban)

patient with doctor image


ELIQUIS® is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).3

patient with doctor image 2

ELIQUIS in VTE Treatment & Prevention

ELIQUIS® is indicated for the treatment of DVT and PE, and the prevention of recurrent DVT and PE, in adults.3

patient with doctor image 3

ELIQUIS in VTE Prophylaxis

ELIQUIS® is indicated for the prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery3.


Risk Minimisation Materials

The Eliquis (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications as an aid to prescribing, in particular they are aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk. Printed copies of these educational materials may be obtained by contacting the Bristol-Myers Squibb Medical Information Department (telephone: 1800 749 749; e-mail: Alternatively, electronic copies can be accessed via the HPRA website at


  1. Granger CB et al. N Engl J Med 2011; 365: 981-992
  2. Giugliano RP et al. N Engl J Med 2013; 369:2
  3. ELIQUIS (apixaban) Summary of Product Characteristics